• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

SPACs Aren't Just for Trading: 2 Attractive Buy and Hold Opportunities

I like putting some of my money with incredibly successful folks who are well-connected and have a history of success.
By TIMOTHY COLLINS
Jun 19, 2020 | 12:31 PM EDT
Stocks quotes in this article: FMCI, ARYA, STWD, AMGN, GMAB, BMY, GSK, ABBV

Special Purpose Acquisition Companies, or SPACs, continue to provide fantastic trading opportunities. And I believe there are some buy and hold opportunities in this space as well.

I've already professed my admiration for Forum Merger II (FMCI) , which will soon be known as Tattooed Chef. However, the stock has bounced almost 50% since my writeup last Friday, so an investor is now paying closer to the lower end of the trading range I see over the next 12 months.

The two buy-and-hold names I would consider here offer both sides of the coin. One with no deal in place nor any letter of intent signed. The other will have its merger vote a week from Monday.

First up is recent creation Jaws Acquisition Corp. (JWS.U). This is a unit rather than a stock or a warrant. A unit is a combination of stock and warrant until the two begin trading separately, so this is very early in its life. In this case, each unit consists of one Class A share and one-third of one redeemable warrant which can be used to buy shares at $11.50. Initially, the company intended to raise $460 million, but demand drove that to $600 million with another $90 million for over-allotment.

The big draw for Jaws is the chairman: Barry Sternlicht. Despite Sternlicht's involvement the company does not intend to pursue real estate, lodging, or energy infrastructure. Given the current economy, I find that a good move.

Sternlicht is also the chairman of Starwood Property Trust (STWD) as well as the chairman and CEO of Starwood Capital. With degrees from Brown and Harvard in addition to his work on Wall Street, this is the type of person you want in charge.

I wouldn't expect any immediate pops to the $15 or $20 level on this one. It may actually require some patience, but the downside should be limited.

On the flipside is Arya Sciences Acquisition Corp. (ARYA) , which is set to vote on its proposed acquisition of Immatics on June 29. Immatics has a strong T cell receptor-based pipeline in the immunotherapy approach to cancer treatment.

It's a Friday, so I doubt most folks want to get into the impressive science Immatics already showcases, but what should catch your eye, if nothing else, is the strategic partners Immatics has already.

Look at this list: Amgen (AMGN) , Genmab (GMAB) , Bristol-Myers Squibb (BMY) , Roche (RHHBY), and GlaxoSmithKline (GSK) .

Not mentioned on the chart above is the fact that Genmab entered into a collaboration with AbbVie (ABBV) to joint develop and commercialize three of Genmab's bispecific antibody products. If we dig into Immatics a bit, we'll find they entered the partnership with Genmab in 2018 (and received $54 million upfront) to create bispecific therapies.

The deal with Glaxo announced earlier this year included a $50 million upfront payment for the develop of Adoptive Cell Therapies to treat cancer.

Immatics offers the potential best of both worlds -- a partnership platform plus developing clinical-stage products. The company has four trials under way with MD Anderson Cancer Center with the potential for several more treatments to move into clinic soon. And the CEO has already said Immatics is considering entering another strategic alliance with a large player in the field of cell therapy.

Post-merger, Immatics should have well over $300 million cash on its balance sheet. Market cap will land in the $850 million range, based on current prices, but I believe this should be in the $1.25 billion to $1.5 billion range based on current peer valuations.

Lastly, this SPAC is sponsored by Perceptive Advisors and Joe Edelman. In terms of biotech, Edelman is a rock star. If there's a huge mover, he has his hand in it somewhere.

Perceptive's returns over the past two decades are matched by few. Similar to the idea above with Sternlicht, I like putting some of my money with incredibly successful folks that are well-connected and have a history of success.

With all the speculative SPACs flying around traders' screens right now these are two I believe have value and significant upside potential, before those speculative names. In two years, I expect both of these names to be trading at two to three times their current prices.

Tim Collins provides options trade ideas each day on Real Money Pro, our sister site for active traders. Click here to learn more and get great columns, commentary and trade ideas from Tim Collins, Mark Sebastian, Paul Price, Doug Kass, and others.

(Bristol-Myers Squibb and ABBV are holdings in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells these stocks? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Collins was long ARYA, JWS.U.

Please note that due to factors including low market capitalization and/or insufficient public float, we consider these names to be a small-cap stocks. You should be aware that such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information, and that postings such as this one can have an effect on their stock prices.

TAGS: Mergers and Acquisitions | Takeover Possibility | Investing | Markets | Small Cap | Stocks | Trading

More from Stocks

The Psilocybin Patent Race Is On

Debra Borchardt
Mar 6, 2021 12:30 PM EST

It feels like these companies are casting a wide net, but it makes sense to file at the beginning of this mushroom mania.

The Challenge of Short Selling

James "Rev Shark" DePorre
Mar 6, 2021 10:00 AM EST

Short selling is a powerful tool, but it is not just the inverse of going long and requires a very different mindset to do it effectively.

Kass: There Are Many Reasons to Be a Bear

Doug Kass
Mar 6, 2021 8:15 AM EST

I believe the markets are headed lower - probably not in a straight line or as steep as the last few days, but in a saw tooth fashion lower.

Bounce Takes Some of the Sting Out of a Painful Week

James "Rev Shark" DePorre
Mar 5, 2021 4:51 PM EST

It is premature to declare that the worst is over, but the intensity of the selling will go a long way toward helping a bottom to form.

The Selloff in Twilio Could Extend Deeper Into March

Bruce Kamich
Mar 5, 2021 2:30 PM EST

TWLO could bounce in the short-run but avoid the long side for now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:38 AM EST GARY BERMAN

    The INDU and DIA

    FIBOCALL: The INDU index and the DIA The INDU ...
  • 10:44 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "The Challenge of Short-Selling"
  • 08:40 AM EST PAUL PRICE

    Recent Pick SpartanNash (SPTN) Raised Its Quarterly Payout by 3.9%

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login